First global guideline sets standards for the use of phages in hard-to-treat infections
An international working group has released the first global guidelines for personalized phage therapy to treat antibiotic-resistant infections. The framework provides standardized protocols for the selection, manufacturing, and clinical application of bacteriophages.
Why it matters
As antibiotic resistance grows, this standardized approach offers a critical, validated pathway for using viruses to treat otherwise incurable bacterial infections.
by Nicola Wittekindt, German Center for Infection Research
edited by Sadie Harley , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Holes in the bacterial colony on an agar plate—these are the first indications of a new bacteriophage. Credit: AG Würstle/Frankfurt University Medical Center An international working group led by the German Society for Infectious Diseases (DGI) has developed a guideline for personalized phage therapy. Twenty professional organizations, 18 international experts, including representatives from regulatory agencies, and two patient advocacy organizations were involved.
The guideline includes more than 60 practice-oriented recommendations on the selection and testing of suitable phages, infrastructure, manufacturing and quality control, application, monitoring, and documentation, as well as future research questions. The consensus statement was published in the journal Nature Medicine .
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in